1. A method for the prevention of hypoglycemia in type 2 diabetes mellitus involves the administration of (a) desPro Exendin-4 (1-39) -Lys-NH or / and its pharmaceutically acceptable salt, and (b) sulfonylurea and / or its pharmaceutically acceptable salt in need thereof to an individual. 2. The method of claim 1, wherein (i) desProExendin-4 (1-39) -Lys-NH or / and its pharmaceutically acceptable salt is administered subcutaneously, and / or (ii) the sulfonylurea or / and its pharmaceutically acceptable salt is administered orally. A method according to any one of claims 1 and 2, wherein desProExendin-4 (1-39) -Lys-NH or / and a pharmaceutically acceptable salt thereof are administered as adjunctive therapy with sulfonylurea. The method of claim 1, wherein type 2 diabetes mellitus is inadequately controlled by the sulfonylurea alone. The method of claim 1, further comprising administering (c) metformin and / or a pharmaceutically acceptable salt thereof, wherein metformin and / or a pharmaceutically acceptable salt thereof is, in particular, administered orally. The method according to claim 5, wherein desProExendin-4 (1-39) -Lys-NH or / and a pharmaceutically acceptable salt thereof are administered as adjunctive therapy with metformin and sulfonylurea. A method according to any one of claims 5 and 6, wherein type 2 diabetes mellitus is inadequately controlled by sulfonylurea and metformin separately. The method according to claim 1, wherein the sulfonylurea is suitable for the treatment of type 2 diabetes and is selected, in particular, from glibenclamide, glibenclamide MR, glyclazide, glyclazide LM, glimepiride, glipizide, glipizide XL, glycuidone, and tolbutamide. The method of claim 1, wherein the individual receiving the treatment is obese, and where the individual, in particular, has a body mass index of at least 30.10. The method according to claim 1, where the individual receiving treatment is1. Способ профилактики гипогликемии при сахарном диабете 2 типа в
